Promising Efficacy of Zenocutuzumab in Treatment-Naïve NRG1+ NSCLC Patients Discussed at IASLC-ASCO NACLC

Promising Efficacy of Zenocutuzumab in NRG1+ NSCLC Patients

In a significant leap forward for oncology therapies, Partner Therapeutics, Inc. recently unveiled compelling new data regarding zenocutuzumab-zbco (BIZENGRI) during the IASLC-ASCO North America Conference on Lung Cancer held in Chicago. The presentation drew attention as it outlined the results from a post hoc analysis of the Phase 2 eNRGy trial (NCT02912949), which focused on patients with treatment-naïve non-small cell lung cancer (NSCLC) harboring the neuregulin 1 (NRG1) gene fusion. This groundbreaking news perpetuates a narrative of hope for a patient population that has traditionally faced limited options.

Efficacy Highlights

The eNRGy trial comprised two distinct groups: a total of 20 treatment-naïve patients and 121 individuals with prior treatments. The results were striking—zenocutuzumab demonstrated an overall response rate (ORR) of 35% in treatment-naïve patients versus 31% in those previously treated. Moreover, the clinical benefit rate, which includes partial or complete response as well as stable disease lasting more than 24 weeks, reached an impressive 65% among the new patients and 58% among the experienced ones. Notably, the median duration of response was significantly longer for treatment-naïve individuals at 17.1 months, compared to 7.4 months for those with previous treatment histories.

All adverse events related to the therapy fell within Grades 1 and 2, and the favorable safety profile was consistent with prior studies, enhancing confidence in zenocutuzumab's therapeutic potential.

Stephen Liu, MD, from Georgetown University, emphasized the significance of the findings.